brachyury Activators
Brachyury activators comprise a diverse array of chemical compounds strategically designed to modulate key signaling pathways intricately involved in the regulation of this transcription factor. Brachyury, a critical regulator in embryonic development and cellular differentiation, plays a pivotal role in the delicate balance between pluripotency and differentiation. Understanding the mechanisms of brachyury activation by various compounds provides valuable insights into the complex regulatory networks governing these fundamental biological processes. Among the activators, CHIR99021 and CHIR98014 act as inhibitors of glycogen synthase kinase-3 (GSK-3), indirectly activating brachyury. By stabilizing β-catenin and promoting its nuclear translocation, these compounds enhance the transcriptional activity and expression of brachyury. This mechanism favors cellular differentiation, highlighting the interconnectedness of Wnt/β-catenin signaling with brachyury regulation. Inhibition of transforming growth factor-beta (TGF-β) signaling represents another avenue for brachyury activation. Compounds like SB431542, LDN-193189, LY364947, and A83-01 target various components of the TGF-β pathway, indirectly activating brachyury by preventing the inhibitory phosphorylation of SMAD2/3.
JNK Inhibitor VIII, IWR-1-endo, and JW74 focus on pathways such as JNK, Wnt, and β-catenin/TCF, respectively. These compounds indirectly impact brachyury activity by modulating these critical signaling pathways, contributing to the fine-tuned control of brachyury expression and function. Inhibitors targeting the MAPK/ERK pathway, such as U0126 and PD98059, represent yet another group of brachyury activators. By influencing downstream targets, including brachyury, these compounds enhance its transcriptional activity and contribute to cellular differentiation. FGFR inhibition with SU5402 introduces an additional layer of complexity to brachyury activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
CHIR99021 is a selective GSK-3 inhibitor that indirectly activates brachyury. By inhibiting GSK-3, it leads to the stabilization and nuclear translocation of β-catenin, which subsequently enhances the transcriptional activity of brachyury. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β type I receptor ALK5, indirectly activating brachyury. By blocking the TGF-β signaling pathway, it prevents the inhibitory phosphorylation of SMAD2/3, leading to increased brachyury expression and activity. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a selective BMP type I receptor inhibitor that indirectly activates brachyury. By inhibiting BMP signaling, it modulates the balance between pluripotency and differentiation, favoring the expression and activation of brachyury. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII is a selective inhibitor of c-Jun N-terminal kinase (JNK), indirectly activating brachyury. By suppressing JNK signaling, it influences the AP-1 transcription factor, which can modulate brachyury expression and enhance its activity. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY364947 is a selective TGF-β receptor kinase inhibitor that indirectly activates brachyury. By suppressing the TGF-β signaling pathway, it prevents the inhibitory phosphorylation of SMAD2/3, leading to increased brachyury expression and activity. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $135.00 | 19 | |
IWR-1-endo is a small molecule that indirectly activates brachyury. It inhibits the Wnt pathway by stabilizing Axin, leading to the degradation of β-catenin and subsequent suppression of Wnt-mediated inhibition of brachyury, resulting in increased activity. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $63.00 $98.00 | 36 | |
SU5402 is a selective FGFR inhibitor that indirectly activates brachyury. By inhibiting FGFR signaling, it influences downstream pathways, including MAPK and PI3K/AKT, which can modulate brachyury expression and enhance its transcriptional activity. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01 is a selective inhibitor of TGF-β type I receptor ALK5, indirectly activating brachyury. By blocking TGF-β signaling, it prevents the inhibitory phosphorylation of SMAD2/3, leading to increased brachyury expression and activity. | ||||||
JW 74 | 863405-60-1 | sc-507506 | 5 mg | $171.00 | ||
JW74 is a β-catenin/TCF inhibitor that indirectly activates brachyury. By inhibiting the interaction between β-catenin and TCF, it suppresses Wnt signaling, allowing for the increased expression and activity of brachyury in the absence of Wnt-mediated inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective MEK1 inhibitor that indirectly activates brachyury. By inhibiting the MAPK/ERK pathway, it modulates downstream targets, including brachyury, which can be upregulated in response to MEK inhibition, leading to enhanced transcriptional activity. | ||||||